Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Daniel B Soland Insider Profile
4 Followers
Daniel B Soland, Director at Oxford BioMedica, holds 1.40M shares in Oxford BioMedica (Ticker: OXBDF). Most recently, Daniel B Soland Bought $500,000 shares of Oxford BioMedica on Jun 09, 2015 for an estimated value of 47.25K.
Daniel B Soland has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of Daniel B Soland's holdings
Insider Roles
Director
Roles that Daniel B Soland holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Daniel B Soland
Daniel B Soland's Trading History
List of latest transactions for each holding click on a transaction to see Daniel B Soland's performance on stock
You May Also Like
Daniel B Soland insider profile FAQ
What is the percentage of profitable transactions made by Daniel B Soland?
The percentage of profitable transactions made by Daniel B Soland is ―.
What is the average return per transaction made by Daniel B Soland?
The average return per transaction made by Daniel B Soland is ―.
What stocks does Daniel B Soland hold?
Daniel B Soland holds: OXBDF stocks.
What was Daniel B Soland’s latest transaction?
Daniel B Soland latest transaction was an Informative Buy of $47.25K.
What was Daniel B Soland's most profitable transaction?
Daniel B Soland’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Daniel B Soland's role in Oxford BioMedica?
Daniel B Soland's role in Oxford BioMedica is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.